Belite Bio Statistics
Total Valuation
Belite Bio has a market cap or net worth of $1.91 billion. The enterprise value is $1.89 billion.
| Market Cap | 1.91B |
| Enterprise Value | 1.89B |
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Belite Bio has 30.88 million shares outstanding. The number of shares has increased by 15.58% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 30.88M |
| Shares Change (YoY) | +15.58% |
| Shares Change (QoQ) | +1.20% |
| Owned by Insiders (%) | 2.73% |
| Owned by Institutions (%) | 0.48% |
| Float | 12.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 17.65 |
| P/TBV Ratio | 17.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 30.73
| Current Ratio | 30.73 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,419.76 |
Financial Efficiency
Return on equity (ROE) is -40.04% and return on invested capital (ROIC) is -26.89%.
| Return on Equity (ROE) | -40.04% |
| Return on Assets (ROA) | -25.58% |
| Return on Capital (ROIC) | -26.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.65M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Belite Bio has paid $5,000 in taxes.
| Income Tax | 5,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +41.78% in the last 52 weeks. The beta is -1.64, so Belite Bio's price volatility has been lower than the market average.
| Beta (5Y) | -1.64 |
| 52-Week Price Change | +41.78% |
| 50-Day Moving Average | 68.79 |
| 200-Day Moving Average | 51.59 |
| Relative Strength Index (RSI) | 42.95 |
| Average Volume (20 Days) | 59,592 |
Short Selling Information
| Short Interest | 232,246 |
| Short Previous Month | 241,075 |
| Short % of Shares Out | 1.79% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.17 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.49M |
| Pretax Income | -31.62M |
| Net Income | -33.03M |
| EBITDA | -35.30M |
| EBIT | -35.49M |
| Earnings Per Share (EPS) | -$1.11 |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | n/a |
| Net Cash | n/a |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 112.20M |
| Book Value Per Share | 3.63 |
| Working Capital | 107.65M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Belite Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.58% |
| Shareholder Yield | -15.58% |
| Earnings Yield | -1.69% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Belite Bio is $89.00, which is 43.57% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $89.00 |
| Price Target Difference | 43.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |